Journal Article Summary
The article investigates the potential liver toxicity associated with tegoprazan, a new type of medication known as a potassium-competitive acid blocker (P-CAB), compared to traditional proton pump inhibitors (PPIs). PPIs are commonly prescribed to manage conditions related to excessive stomach acid, such as heartburn and gastroesophageal reflux disease (GERD). Understanding the safety profile of these medications, particularly regarding liver health, is crucial since previous P-CABs faced issues with hepatotoxicity, raising concerns about the safety of newer alternatives like tegoprazan.
The study utilized a large dataset from South Korea's national health insurance database, which includes comprehensive health records of approximately 50 million people. Researchers conducted a retrospective cohort analysis, comparing the incidence of liver-related health issues between patients prescribed tegoprazan and those taking six different PPIs. The findings indicated that tegoprazan had a significantly lower risk of hepatotoxicity compared to the majority of the PPIs studied, with an overall risk reduction of about 27%. This suggests that tegoprazan may be a safer option for patients in terms of liver health.
However, the study has limitations, including its retrospective design and reliance on diagnostic codes rather than direct laboratory results or imaging tests to define hepatotoxicity. Patients and caregivers should be aware that while tegoprazan appears to have a better safety profile regarding liver toxicity compared to traditional PPIs, individual health factors can influence medication effects. It is advisable for patients to discuss any concerns about liver health and medication options with their healthcare provider to ensure safe and effective treatment choices.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Kim Min-Gul, Im Yong-Jin, Lee Jong-Hwan, Kim Eun-Young, Yeom Sang Woo, Kim Jong Seung. Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study. Frontiers in Medicine 2023. DOI: 10.3389/fmed.2022.1076356. PMID: 36714137. PMCID: PMC9876560.
Featured Pill Pals Product
Pantoprazole 20 mg Enteric Coated Tablets --- Generic For Protonix
Pantoprazole 20 mg Enteric Coated Tablets — Generic For Protonix is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
